Hillstream & ABSI collaborated on licensing of technology for human Abs targeting novel HER2 and HER3 conformational epitopes. The purpose of the agreement is to develop proprietary multi-format biologics, incl. bi-specific Abs and ADCs to combat drug-resistant cancers i.e., HER2+ metastatic breast cancer, gastric cancer, lung cancer, and ovarian cancer
Hillstream to get the rights to develop HER2 and HER3 Abs incl. multi-specific, ADC, and Quatramer-based therapeutics utilizing portions of these Abs
HER2/HER3 binding ADC is designed to have a high drug-to-antibody ratio intended to enhance the bystander-killing effect and be effective against some epithelial tumors
Ref: Globenewswire | Image: Applied Biomedical Science
Related News:- Mersana Therapeutics Reports US FDA’s Partial Clinical Hold on New Patient Enrollment of UpRi for Platinum-Sensitive Ovarian Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
